Abbott launches updated stroke device
This article was originally published in The Gray Sheet
Firm announces CE mark approval and European launch of its Emboshield PRO embolic protection system on Sept. 13. The next-generation device is more radiopaque than its predecessor, providing better X-ray visibility, Abbott says. Its small size and enhanced profile position the device as a new option for tortuous vessels, according to the firm. Separately, on Sept. 12 the firm reported an expansion of its manufacturing facility in Ireland to ramp up production of the Xience V drug-eluting stent, expected to debut in October (1"The Gray Sheet" Sept. 11, 2006, p. 5)...
You may also be interested in...
Abbott is trumpeting the latest findings about its Xience V drug-eluting stent in preparation for next month's European launch
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.